NEUMOLOGÍA PEDIÁTRICA

Neumol Pediatr 2020; 15 (4): 429 - 483 C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl 482 Consenso chileno para la atención integral de niños y adultos con fibrosis quística 2019;23(2):263–77. 131. Debray D, Narkewicz MR, Bodewes FAJA, Colombo C, Housset C, De Jonge HR, et al. Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspec- tives. J Pediatr Gastroenterol Nutr. 2017;65(4):443–8. 132. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and mana- gement of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10(Suppl. 2). 133. Kobelska-Dubiel N, Klincewicz B, Cichy W. Li- ver disease in cystic fibrosis. Prz Gastroenterol. 2014;9(3):136–41. 134. Carlyle BE, Borowitz DS, Glick PL. A review of pa- thophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. J Pediatr Surg. 2012;47(4):772–81. 135. Houwen RH, van der Doef HP, Sermet I, Munck A, Hauser B, Walkowiak J, et al. Defining DIOS and Cons- tipation in Cystic Fibrosis With a Multicentre Study on the Incidence, Characteristics, and Treatment of DIOS. J Pediatr Gastroenterol Nutr. 2010;50(1):38–42. 136. Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10(Suppl. 2). 137. Robinson NB, DiMango E. Prevalence of gastroeso- phageal reflux in cystic fibrosis and implications for lung disease. Ann Am Thorac Soc. 2014;11(6):964–8. 138. Maisonneuve P, FitzSimmons SC, Neglia JP, Cam- pbell PW, Lowenfels AB. Cancer risk in nontransplan- ted and transplanted cystic fibrosis patients: A 10-year study. J Natl Cancer Inst. 2003;95(5):381–7. 139. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: A 20-year nationwi- de study from the United States. J Natl Cancer Inst. 2013;105(2):122–9. 140. Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB, et al. Cystic Fibrosis Co- lorectal Cancer Screening Consensus Recommendations. Gastroenterology. 2018;154(3):736-745.e14. 141. Codner E, Acerini CL, Craig ME, Hofer SE, Maahs DM. ISPAD Clinical Practice Consensus Guidelines 2018: What is new in diabetes care? Pediatr Diabetes. 2018;19:5–6. 142. Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL. ISPAD Clinical Practice Consensus Gui- delines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2018;19:64–74. 143. Assocsiation AD. Standards of Medical Care in Diabetes-2017: Summary of Revisions. Diabetes Care. 2017;40. 144. Sermet-Gaudelus I, Bianchi ML, Garabédian M, Aris RM, Morton A, Hardin DS, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros. 2011;10(Suppl. 2). 145. Fundakowski C, Ojo R, Younis R. Rhinosinusitis in the pediatric patient with cystic fibrosis. En: Pediatric and Adult SinoNasal Disorders. Nova Science Publishers, Inc.; 2015. p. (pp. 171–179). 146. Mainz JG, Koitschev A. Pathogenesis and manage- ment of nasal polyposis in cystic fibrosis. Curr Allergy Asthma Rep. 2012;12(2):163–74. 147. Selimoglu E. Aminoglycoside-Induced Ototoxicity. Curr Pharm Des. 2006;13(1):119–26. 148. Smyth AR, Bhatt J, Nevitt SJ. Once-daily versus multiple-daily dosing with intravenous aminoglyco- sides for cystic fibrosis. Cochrane Database Syst Rev. 2017;3(3):CD002009. 149. Kranzer K, Elamin WF, Cox H, Seddon JA, Ford N, Drobniewski F. A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in pre- venting aminoglycoside-induced ototoxicity: Implica- tions for the treatment of multidrug-resistant TB. Thorax. 2015;70(11):1070–7. 150. Clarke EA, Watson P, Freeston JE, Peckham DG, Jo- nes AM, Horsley A. Assessing arthritis in the context of cystic fibrosis. Pediatr Pulmonol. 2019;54(6):770–7. 151. Nazareth D, Walshaw M. A review of renal disease in cystic fibrosis. J Cyst Fibros. 2013;12(4):309–17. 152. Gibney EM, Goldfarb DS. The association of nephro- lithiasis with cystic fibrosis. Am J Kidney Dis. 2003;42(1 Suppl. 2):1–11. 153. Lai S, Mazzaferro S, Mitterhofer AP, Bonci E, Marotta PG, Pelligra F, et al. Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis. J Transl Med. 2019;17(1). 154. Fox S, Farr-Jones S, Sopchak L, Boggs A, Ni- cely HW, Khoury R, et al. High-throughput screening: Update on practices and success. J Biomol Screen. 2006;11(7):864–9. 155. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CF- TR mutation: A double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(7):524–33. 156. Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018;6(7):545–53. 157. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, D ř evínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–72. 158. Middleton PG, Mall MA, D ř evínek P, Lands LC, Mc- Kone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaf- tor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809–19. 159. Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612–20. 160. Heijerman HGM, McKone EF, Downey DG, Van Braec- kel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination re- gimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3